摘要
目的探讨注射给药唑来膦酸结合经皮椎体成形注射骨水泥治疗骨质疏松性椎体压缩骨折（OVCF）的临床效果，分析对其症状或体征改善作用，并观察其预后。方法选择2013-年月至2014年9月进行治疗的OVCF患者158例，随机分为观察组和对照组，每组各79例，对照组应用经皮椎体成形注射骨水泥治疗，观察组应用唑来膦酸联合经皮椎体成形注射骨水泥治疗。采用视觉模拟评分法（VAS）评估患者的疼痛状况，采用Oswestry功能障碍指数问卷表（ODI）评估患者的功能障碍指数，检测患者L1-4及股骨颈骨密度。结果观察组患者治疗3个月和6个月后VAS和ODI分别为（3．62±0．71）分、（2．27±0．64）分和（69．51±7．44）％、（55．06±6．93）％，均低于对照组（4．93±0．68）分、（3．04±0．59）分和（73．40±7．26）％、（62．51±7．30）％，差异均具有统计学意义（P〈0．05）；观察组患者治疗1年后L1-4和股骨颈骨密度结果分别为（0．77±0．15）g／cm^2和（0．77±0．15）g／cm^2，均高于对照组（0．72±0．12）g／cm^2和（O．73±0．21）g／cm^2，差异具有统计学意义（P〈0．05）；两组患者治疗后不良反应结果比较，差异均无统计学意义（P〉0．05）。结论注射给药唑来膦酸结合经皮骨水泥椎体成形治疗OVCF患者可明显减轻患者疼痛．改善患者功能．增强患者骨密度．并具有较好的安全性．
Objective To explore the clinical effect the on Zoledronic acid combined with percutaneous injection of bone cement vertebroplasty for treatment of osteoporotic vertebral compression fracture （ OVCF ） , and to observe the improvement of symptoms or signs, and to observe the prognosis. Methods 158 patients with OVCF were selected in hospital from January in 2013 to September in 2014, they were randomly divided into the observation group and the control group, 79 cases in each group.The control group was given percutaneous injection of bone cement vertebroplasty treatment, and the observation group used zoledronic acid combined with percutaneous vertebroplasty injection of bone cement treatment.Assessed pain status by visual analogue scale （ VAS ） and the dysfunction by the Oswestry Disability Index questionnaire （ ODI ） index, detected BMD of lumbar spine L1-4 and femoral neck. Results The VAS and ODI of the observation group after three and six months were （ 3.62 ± 0.71 ） points, （2.27±0.64） points and （69.51±7.44） %, （55.06±6.93） %, lower than the control group （4.93±0.68） points, （3.04±0.59） points and （ 73.40 ± 7.26 ） %, （ 62.51 ± 7.30 ） %, the difference was statistically significant （ P〈0.05 ） . BMD of lumbar L1- 4 and femur neck Results of the observation group after treatment one year were （ 0.77 ± 0.15 ） g/cm^2 and （ 0.77 ± 0.15 ） g/cm^2, higher than the control group （ 0.72 ± 0.12 ） g/cm^2 and （ 0.73 ± 0.21 ） g/cm^2, the differences were statistically significant （ P〈0.05 ） .When comparing the adverse results of two groups, the difference was not statistically significant （ P〉0.05 ） . Conclusion Application of zoledronic acid combined with percutaneous injection of bone cement vertebroplasty treatment OVCF patients can significantly reduce pain and improve function, enhance patient bone density and is safer.
出处
《浙江临床医学》
2016年第4期597-599,共3页
Zhejiang Clinical Medical Journal
基金
浙江省医药卫生一般研究计划（B类）（2012KYB251）
关键词
唑来膦酸
经皮椎体成形术
骨质疏松
椎体压缩骨折
临床效果
Zoledronic acid Percutaneous vertebroplasty Osteoporosis Vertebral compression fractures Clinical effect
